The Comparison of the Quality of Life in Patients with Early Stage Breast Cancer between using FAC and AC-T Regimens in Marengrairoke Clinic at Maharat Nakhon Ratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Introduction: There are few studies on the quality of life and the comparative research of chemotherapy regimens on quality of life in breast cancer patients. This study aimed to compare the quality of life in patients with early stage breast cancer after breast surgery between using FAC (fluorouracil, doxorubicin, cyclophosphamide) and AC-T (doxorubicin, cyclophosphamide, followed by docetaxel or paclitaxel) regimens. The quality of life before and after receiving chemotherapy in each regimen was evaluated. Methods: The 9-month analytical prospective study was conducted in outpatients with early stage breast cancer at MaharatNakhonRatchasima Hospital. The participants were divided into FAC or AC-T regimen groups after they received the FAC or AC-T regimen.. Results: A total of 43 eligible patients were included, 23 in the FAC regimen group and 20 in the AC-T regimen group. There was no difference between baseline characteristics and the quality of life of the two groups. In the FAC regimen group, the physical well-being score of the last cycle of chemotherapy was lower than the score before receiving chemotherapy (p=0.009) whereas the emotional well-being score and additional concerns were statistically better (p=0.008 and 0.027, respectively). In the AC-T regimen group, the quality of life in physical well-being at the third and the sixth cycles were statistically lower than before receiving chemotherapy (p=0.005 and p=0.028, respectively). At the last cycle, when compared with baseline, the quality of life in physical well-being, social/family well-being, emotional well-being, functional well-being and overall quality of life were not significantly different, whereas the quality of life in additional concerns at the last cycle of chemotherapy was significantly higher (p=0.013). Comparison of the two regimens at the last cycle revealed that the quality of life in physical well-being of the AC-T regimen group was statistically greater than the FAC regimen group (p=0.012). Conclusion: Participants in the FAC group experienced a lower quality of life in physical well-being before receiving chemotherapy whereas participants in the AC-T group experienced a lower quality of life in physical well-being during the beginning of treatment. Therefore, the results of this comparative study of two regimens indicate that the AC-T regimen is more suitable for patients with concurrent physical health problems.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Bureau of policy and stategy [Online]. [cited 2013 Feb 28 ]. Available from: http://bps.ops.moph.go.th/index.php?mod=bps&doc=5.
Chuchart K, Pruegsanurak K, Dachapunkul T, et al. Quality of life (QoL) in patients suffering from locally advanced-stage nasopharyngeal cancer before, during and after recieiving carboplatin with concurrent chemoradiotherapy. Songkla Med J 2010;28(3):127-137.
Cushnie B, Hatsarin S. Effect of pharmaceutical care among breast-cancer patients undergoing chemotherapy at Udonthani Regional Center,Thailand.Thai Cancer J 2011;31(3):93-105.
Eng J. Sample size estimation: How many individuals should be studied?. Radiol 2003;227:309-313.
Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014: NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014; 12: 542-590.
Hatam N, Ahmadloo N, Kia Daliri AA, et al. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fl uorouracil). Arch Gynecol Obstet 2011;284:215-220.
Jitnumsub P. Quility of life in acute leukemia patients in Siriraj Hospital [dissertation]. Nakhonpathom:
Silpakorn University; 2009.
Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 2006;18(1):24-28.
Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fl uorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205-1212.
Puwarawuttipanit W, Sasitornvechakul T, Weeranun S. Quality of life in patient post mastectomy. Nopparat Raj Hosp Med J 1998; 9(3): 40-52.
Sookprasert A. A step by step practical guide before giving chemotherapy. Workshop and traineeship for oncology pharmacy practitioners, 2011.
Techapongsatorn S, Kasetsermviriya W, Srimantayamas S, et al. Quality of life in breast cancer patients. Vajira Med J 2007;51(1):33-39.
The Functional Assessment of Chronic Illness Therapy (FACIT) measurement [Internet]. [cited 2013 Mar 4]. Available from: http://www.facit.org.
Thongsai P, Suksakorn P, Narasong P. Quality of life in the patients with breast cancer. Siriraj Nurs J 2008; 2(2): 24-34.